Ehud Mekori-Domachevsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ehud Mekori-Domachevsky has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Doron Gothelf
Child and Adolescent Psychiatry Division, Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, IsraelSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
5 shared publicationsMichal Taler
Pediatric Molecular Psychiatry Laboratory, Sheba Medical Center, Ramat Gan, IsraelSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
4 shared publications- Asia Avinir
School of Behavioral Sciences, The Academic College of Tel-Aviv—Yaffo, Tel Aviv 6818211, Israel
3 shared publications - Doron Gothelf
Department of Child and Adolescent Psychiatry, Sheba Hospital, Ramat Gan, Israel
2 shared publications - Mariela Mosheva
The Child Psychiatry Division, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 5262000, Tel Hashomer, Israel.
2 shared publications - Nimrod Hertz-Palmor
University of Cambridge
2 shared publications
Latest Publications
- Open Access
- 6 March 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (5) , 765
Child and Adolescent Mental Health during the COVID-19 Pandemic: Challenges of Psychiatric Outpatient Clinics
Background: Worldwide national surveys show a rising mental health burden among children and adolescents (C&A) during COVID-19. The objective of the current study is to verify the expected rise in visits to psychiatric outpatient clinics of C&A, especially of new patients. Methods: a cross-sectional study focusing on visits as recorded in electronic medical records of eight heterogeneous C&A psychiatric outpatient clinics. The assessment was based on visits held from March to December of 2019 (before the pandemic) in comparison to visits held in 2020 (during the pandemic). Results: The number of visits was similar for both periods. However, in 2020, 17% of the visits used telepsychiatry (N = 9885). Excluding telepsychiatry reveals a monthly decrease in traditional in-person activities between 2020 and 2019 (691.6 ± 370.8 in 2020 vs. 809.1 ± 422.8 in 2019, mean difference = −117.5, t (69) = −4.07, p = 0.0002, Cohen’s d = −0.30). Acceptation of new patients declined during 2020, compared to 2019 (50.0 ± 38.2 in 2020 vs. 62.8 ± 42.9 in 2019; Z = −3.12, p = 0.002, r = 0.44). Telepsychiatry was not used for new patients. Conclusions: The activity of C&A psychiatric outpatient clinics did not rise but was guarded due to the use of telepsychiatry. The decline in visits of new patients was explained by the lack of use of telepsychiatry for these patients. This calls for expanding the use of telepsychiatry, especially for new patients.
- 6 March 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (5) , 765
Open AccessChild and Adolescent Mental Health during the COVID-19 Pandemic: Challenges of Psychiatric Outpatient Clinics
Background: Worldwide national surveys show a rising mental health burden among children and adolescents (C&A) during COVID-19. The objective of the current study is to verify the expected rise in visits to psychiatric outpatient clinics of C&A, especially of new patients. Methods: a cross-sectional study focusing on visits as recorded in electronic medical records of eight heterogeneous C&A psychiatric outpatient clinics. The assessment was based on visits held from March to December of 2019 (before the pandemic) in comparison to visits held in 2020 (during the pandemic). Results: The number of visits was similar for both periods. However, in 2020, 17% of the visits used telepsychiatry (N = 9885). Excluding telepsychiatry reveals a monthly decrease in traditional in-person activities between 2020 and 2019 (691.6 ± 370.8 in 2020 vs. 809.1 ± 422.8 in 2019, mean difference = −117.5, t (69) = −4.07, p = 0.0002, Cohen’s d = −0.30). Acceptation of new patients declined during 2020, compared to 2019 (50.0 ± 38.2 in 2020 vs. 62.8 ± 42.9 in 2019; Z = −3.12, p = 0.002, r = 0.44). Telepsychiatry was not used for new patients. Conclusions: The activity of C&A psychiatric outpatient clinics did not rise but was guarded due to the use of telepsychiatry. The decline in visits of new patients was explained by the lack of use of telepsychiatry for these patients. This calls for expanding the use of telepsychiatry, especially for new patients.
- Open Access
A 16-Month Longitudinal Investigation of Risk and Protective Factors for Mental Health Outcomes Throughout Three National Lockdowns and a Mass Vaccination Campaign: Evidence from a Weighted Israeli Sample During COVID-19
Background: The COVID-19 pandemic is an ongoing global crisis, with a multitude of factors that affect mental health worldwide. Here, we explore potential predictors for the emergence and maintenance of depression, anxiety, and posttraumatic stress symptoms (PTSS) in the general population in Israel. Methods: Across the span of 16 months, 2,478 people completed a repeated self-report survey which inquired psychiatric symptoms and pandemic related stress factors (PRSF). PRSF were divided into four clusters of environmental stressors: financial, health-related, fatigue and sense of protection by authorities. We applied mixed-effects linear models to assess how each stressor contributes to depression, anxiety and PTSS at each time point, alongside a longitudinal exploration among participants who completed at least two consecutive surveys ( n =400). Results: Fatigue was the strongest predictor for depression, anxiety and PTSS at all time points ( standardized β between 0.28-0.60, p <.0001), and predicted deterioration overtime ( β between 0.22-0.36, p <.0001). Financial concerns associated with depression and anxiety at all time points ( β between 0.13- 0.26, p <.01), and with their deterioration overtime ( β between 0.16-0.18, p <.0001), while health related concerns were uniquely associated with anxiety and PTSS at all time points ( β between 0.14-0.29, p <.01) and their deterioration ( β between 0.11-0.16, p <.001), but not with depression. Improvement in sense of protection overtime associated with decrease in depression and anxiety ( β between −0.09 to −0.16, p <.01). Conclusions: Our findings accentuate the multitude of risk factors for psychiatric morbidity during COVID-19, and the dynamics in their association with different aspects of psychopathology at various time points.
Open AccessA 16-Month Longitudinal Investigation of Risk and Protective Factors for Mental Health Outcomes Throughout Three National Lockdowns and a Mass Vaccination Campaign: Evidence from a Weighted Israeli Sample During COVID-19
Background: The COVID-19 pandemic is an ongoing global crisis, with a multitude of factors that affect mental health worldwide. Here, we explore potential predictors for the emergence and maintenance of depression, anxiety, and posttraumatic stress symptoms (PTSS) in the general population in Israel. Methods: Across the span of 16 months, 2,478 people completed a repeated self-report survey which inquired psychiatric symptoms and pandemic related stress factors (PRSF). PRSF were divided into four clusters of environmental stressors: financial, health-related, fatigue and sense of protection by authorities. We applied mixed-effects linear models to assess how each stressor contributes to depression, anxiety and PTSS at each time point, alongside a longitudinal exploration among participants who completed at least two consecutive surveys ( n =400). Results: Fatigue was the strongest predictor for depression, anxiety and PTSS at all time points ( standardized β between 0.28-0.60, p <.0001), and predicted deterioration overtime ( β between 0.22-0.36, p <.0001). Financial concerns associated with depression and anxiety at all time points ( β between 0.13- 0.26, p <.01), and with their deterioration overtime ( β between 0.16-0.18, p <.0001), while health related concerns were uniquely associated with anxiety and PTSS at all time points ( β between 0.14-0.29, p <.01) and their deterioration ( β between 0.11-0.16, p <.001), but not with depression. Improvement in sense of protection overtime associated with decrease in depression and anxiety ( β between −0.09 to −0.16, p <.01). Conclusions: Our findings accentuate the multitude of risk factors for psychiatric morbidity during COVID-19, and the dynamics in their association with different aspects of psychopathology at various time points.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 15
Keeping it simple: mental health assessment in the Gastroenterology Department – using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel
Background: Depression and anxiety are common among inflammatory bowel disease (IBD) patients. Not only do they worsen quality of life, but also worsen the prognosis of the IBD. Yet, there are no widely accepted guidelines for screening for depression or anxiety in this population. The Hospital Anxiety and Depression Scale (HADS) is a self-administered questionnaire designed to measure anxiety and depression in the physically ill. The purpose of this study was to establish the utility of the HADS as a screening tool in IBD patients. Methods: Seventy-nine IBD patients (age 29.86 ± 8.36, 51.9% female, 77.2% Crohn’s disease) were recruited consecutively at the day treatment unit, Gastroenterology Department, Sheba Medical Center. They were asked to complete the HADS, the Beck Depression Inventory (BDI), and the State-Trait Anxiety Inventory (STAI). The scores of the HADS depression and anxiety subscales were correlated with the BDI and STAI scores, and the rates of above-threshold scores were calculated and compared between the three questionnaires and findings from previous studies. Results: The two HADS subscales significantly correlated with and the BDI ( rs = .69, p < 0.001) and STAI state and trait anxiety ( rs = .853, p < 0.001; rs = .744, p < 0.001, respectively). The usual HADS cut-off scores yielded adequate rate of anxiety but lower than expected depression rates. Conclusions: Our findings suggest the HADS as a valid screening tool for anxiety and depression in IBD patients. We recommend administering it routinely in gastrointestinal (GI) follow-ups using a lower cut-off score for depression than anxiety (greater than 7 vs greater than 11, respectively).
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 15
Open AccessKeeping it simple: mental health assessment in the Gastroenterology Department – using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel
Background: Depression and anxiety are common among inflammatory bowel disease (IBD) patients. Not only do they worsen quality of life, but also worsen the prognosis of the IBD. Yet, there are no widely accepted guidelines for screening for depression or anxiety in this population. The Hospital Anxiety and Depression Scale (HADS) is a self-administered questionnaire designed to measure anxiety and depression in the physically ill. The purpose of this study was to establish the utility of the HADS as a screening tool in IBD patients. Methods: Seventy-nine IBD patients (age 29.86 ± 8.36, 51.9% female, 77.2% Crohn’s disease) were recruited consecutively at the day treatment unit, Gastroenterology Department, Sheba Medical Center. They were asked to complete the HADS, the Beck Depression Inventory (BDI), and the State-Trait Anxiety Inventory (STAI). The scores of the HADS depression and anxiety subscales were correlated with the BDI and STAI scores, and the rates of above-threshold scores were calculated and compared between the three questionnaires and findings from previous studies. Results: The two HADS subscales significantly correlated with and the BDI ( rs = .69, p < 0.001) and STAI state and trait anxiety ( rs = .853, p < 0.001; rs = .744, p < 0.001, respectively). The usual HADS cut-off scores yielded adequate rate of anxiety but lower than expected depression rates. Conclusions: Our findings suggest the HADS as a valid screening tool for anxiety and depression in IBD patients. We recommend administering it routinely in gastrointestinal (GI) follow-ups using a lower cut-off score for depression than anxiety (greater than 7 vs greater than 11, respectively).
- 30 July 2021
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 29 (9) , 725-730
Internalizing symptoms impede adolescents’ ability to transition from in-person to online mental health services during the 2019 coronavirus disease pandemic
Introduction: Online mental health services were previously found to be effective in many studies. However, this method was not generally used in Israel. By the end of 2019, the coronavirus disease 2019 pandemic erupted, forcing mental health services to transition to online meetings to maintain the standard of care. In this cross-sectional study, we investigated the attitudes of adolescent patients toward this involuntary new mode of care. Methods: Forty-four adolescents (mean age 14.62 ± 2.12 years, 54.5% females) and 40 of their primary caregivers completed a battery of questionnaires that included the telemedicine satisfaction questionnaire, session evaluation questionnaire, working alliance inventory, and pediatric symptom checklist. Results: Both adolescents and their caregivers reported a reasonable experience with the online medium and a feeling that the meetings were overall powerful, helpful, and comfortable as demonstrated by medium to high scores on the telemedicine satisfaction questionnaire and session evaluation questionnaire questionnaires. A therapeutic alliance was generally maintained according to working alliance inventory scores. However, working alliance inventory scores were negatively correlated with higher levels of internalizing symptoms and parental stress. Discussion: Our findings point to the possibility that anxious/depressed adolescents will have greater difficulties re-establishing therapeutic alliance when transitioned from in-person to online meetings. This may be due to the introduction of an “invisible” third party to the therapeutic setting—the computer. Psychologists and psychiatrists should be aware of these difficulties and respond adequately to maintain the standard of care.
- 30 July 2021
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 29 (9) , 725-730
Internalizing symptoms impede adolescents’ ability to transition from in-person to online mental health services during the 2019 coronavirus disease pandemic
Introduction: Online mental health services were previously found to be effective in many studies. However, this method was not generally used in Israel. By the end of 2019, the coronavirus disease 2019 pandemic erupted, forcing mental health services to transition to online meetings to maintain the standard of care. In this cross-sectional study, we investigated the attitudes of adolescent patients toward this involuntary new mode of care. Methods: Forty-four adolescents (mean age 14.62 ± 2.12 years, 54.5% females) and 40 of their primary caregivers completed a battery of questionnaires that included the telemedicine satisfaction questionnaire, session evaluation questionnaire, working alliance inventory, and pediatric symptom checklist. Results: Both adolescents and their caregivers reported a reasonable experience with the online medium and a feeling that the meetings were overall powerful, helpful, and comfortable as demonstrated by medium to high scores on the telemedicine satisfaction questionnaire and session evaluation questionnaire questionnaires. A therapeutic alliance was generally maintained according to working alliance inventory scores. However, working alliance inventory scores were negatively correlated with higher levels of internalizing symptoms and parental stress. Discussion: Our findings point to the possibility that anxious/depressed adolescents will have greater difficulties re-establishing therapeutic alliance when transitioned from in-person to online meetings. This may be due to the introduction of an “invisible” third party to the therapeutic setting—the computer. Psychologists and psychiatrists should be aware of these difficulties and respond adequately to maintain the standard of care.
- 1 May 2021
- Published by Elsevier in Schizophrenia Research
- Vol. 231, 164-169
Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome – Clinical and scientific implications
- 1 May 2021
- Published by Elsevier in Schizophrenia Research
- Vol. 231, 164-169
Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome – Clinical and scientific implications
- 23 February 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (7) , 1083-1084
Body, Soul, and Hypnotherapy
- 23 February 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (7) , 1083-1084
Body, Soul, and Hypnotherapy
- 14 December 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 461-468
Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome
22q11.2 deletion syndrome (22q11.DS) is a neurogenetic disorder caused by a microdeletion in chromosome 22. Its phenotype includes high rates of psychiatric disorders, immune system abnormalities, and cognitive impairments. We assessed the quality of sleep in 22q11.2DS and its potential link to inflammatory markers and cognitive deficits. Thirty‐three 22q11.2DS individuals and 24 healthy controls were studied. Sleep parameters were assessed by the Pittsburgh sleep quality index (PSQI) questionnaire and correlated with serum cytokine levels and cognitive functioning, measured using the Penn computerized neurocognitive battery (CNB). The 22q11.2DS individuals had significantly worse sleep quality scores than the controls, unrelated to the psychiatric or physical comorbidities common to 22q11.2DS. Interleukin 6 levels were correlated with the overall score of the PSQI questionnaire for nonpsychotic 22q11.2DS participants only. Several domains of the CNB were associated with poorer sleep quality, suggesting that cognitive impairments in 22q11.2DS may be at least partially explained by poor sleep quality. Our findings confirm sleep impairments in individuals with 22q11.2DS, which might negatively affect their cognitive functioning, and corroborate a potential role of immunological pathways in the 22q11.2DS neuro‐phenotype.
- 14 December 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 461-468
Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome
22q11.2 deletion syndrome (22q11.DS) is a neurogenetic disorder caused by a microdeletion in chromosome 22. Its phenotype includes high rates of psychiatric disorders, immune system abnormalities, and cognitive impairments. We assessed the quality of sleep in 22q11.2DS and its potential link to inflammatory markers and cognitive deficits. Thirty‐three 22q11.2DS individuals and 24 healthy controls were studied. Sleep parameters were assessed by the Pittsburgh sleep quality index (PSQI) questionnaire and correlated with serum cytokine levels and cognitive functioning, measured using the Penn computerized neurocognitive battery (CNB). The 22q11.2DS individuals had significantly worse sleep quality scores than the controls, unrelated to the psychiatric or physical comorbidities common to 22q11.2DS. Interleukin 6 levels were correlated with the overall score of the PSQI questionnaire for nonpsychotic 22q11.2DS participants only. Several domains of the CNB were associated with poorer sleep quality, suggesting that cognitive impairments in 22q11.2DS may be at least partially explained by poor sleep quality. Our findings confirm sleep impairments in individuals with 22q11.2DS, which might negatively affect their cognitive functioning, and corroborate a potential role of immunological pathways in the 22q11.2DS neuro‐phenotype.
- Open Access
- 13 December 2019
- Published by Springer Nature in Research Square
Antipsychotic Drugs Attenuate Interleukin-6 Secretion by Microglia Via Dopamine Inhibition
Background: Antipsychotic drugs are commonly used for various neuropsychiatric disorders, such as psychotic disorders, mood disorders, and neuropsychiatric symptoms in dementia. Their mechanism of action is thought to be by modulation of neurotransmitter activity in the brain, mainly dopamine. It has been suggested that antipsychotic drugs may also exert anti-inflammatory properties. This study aimed to examine whether the modulating effect of antipsychotic drugs on neurotransmitters attenuates the inflammatory response of microglia cells. Methods: Levels of interleukin 6 (IL-6) were measured following activation of microglia cultures with lipopolysaccharides and treatment with antipsychotic drugs (risperidone, haloperidol, and clozapine), neurotransmitters (dopamine, serotonin, and acetylcholine), or a combination of dopamine and either haloperidol or clozapine. Results: Haloperidol and clozapine decreased IL-6 secretion by microglia cells when treated at a concentration of 10-5M. Interestingly, dopamine at a concentration of 1 μM increased IL-6 secretion by the microglia cells, while a concentration of 100 μM decreased it. The combination of dopamine (from 0.001 μM to 100 μM) with either haloperidol (10-5M or 10-8M) or clozapine (10-5M or 10-7M) attenuated IL-6 secretion in a bell-shaped curve with a peak at 1 μM. High concentrations of both haloperidol and clozapine decreased IL-6 secretion, while low concentrations modestly increased IL-6 levels. Conclusions: Our findings support anti-inflammatory properties of antipsychotic drugs, and suggest that their action is mediated via the inhibition of dopaminergic activity in microglia cells. The bell-shaped curve of IL-6 secretion by microglia might suggest the presence of an “optimal zone” of operation for these cells that is mediated by dopamine.
- 13 December 2019
- Published by Springer Nature in Research Square
Open AccessAntipsychotic Drugs Attenuate Interleukin-6 Secretion by Microglia Via Dopamine Inhibition
Background: Antipsychotic drugs are commonly used for various neuropsychiatric disorders, such as psychotic disorders, mood disorders, and neuropsychiatric symptoms in dementia. Their mechanism of action is thought to be by modulation of neurotransmitter activity in the brain, mainly dopamine. It has been suggested that antipsychotic drugs may also exert anti-inflammatory properties. This study aimed to examine whether the modulating effect of antipsychotic drugs on neurotransmitters attenuates the inflammatory response of microglia cells. Methods: Levels of interleukin 6 (IL-6) were measured following activation of microglia cultures with lipopolysaccharides and treatment with antipsychotic drugs (risperidone, haloperidol, and clozapine), neurotransmitters (dopamine, serotonin, and acetylcholine), or a combination of dopamine and either haloperidol or clozapine. Results: Haloperidol and clozapine decreased IL-6 secretion by microglia cells when treated at a concentration of 10-5M. Interestingly, dopamine at a concentration of 1 μM increased IL-6 secretion by the microglia cells, while a concentration of 100 μM decreased it. The combination of dopamine (from 0.001 μM to 100 μM) with either haloperidol (10-5M or 10-8M) or clozapine (10-5M or 10-7M) attenuated IL-6 secretion in a bell-shaped curve with a peak at 1 μM. High concentrations of both haloperidol and clozapine decreased IL-6 secretion, while low concentrations modestly increased IL-6 levels. Conclusions: Our findings support anti-inflammatory properties of antipsychotic drugs, and suggest that their action is mediated via the inhibition of dopaminergic activity in microglia cells. The bell-shaped curve of IL-6 secretion by microglia might suggest the presence of an “optimal zone” of operation for these cells that is mediated by dopamine.
- 27 December 2017
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 78 (9) , e1219-e1225
Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits
22q11.2 deletion syndrome (22q11.2DS) is a neurogenetic disorder whose phenotype includes high rates of a schizophrenia-like psychotic disorder and immune system abnormalities. Thus, 22q11.2DS is an ideal model for studying the relationship between psychosis and inflammation. The aim of the present study was to identify inflammatory markers that may play a role in the pathophysiologic pathways associated with psychosis and cognitive deficits in 22q11.2DS. Forty-nine individuals with 22q11.2DS (13 with psychotic disorders according to DSM-IV criteria and 36 without psychotic disorders) and 30 age- and sex-matched healthy controls underwent psychiatric and cognitive assessments at an outpatient clinic. Blood samples from all participants were analyzed for C-reactive protein (CRP), interleukin (IL)-6, IL-10, tumor necrosis factor alpha (TNFα), and IL-1 receptor antagonist levels. The study was conducted between August 2014 and September 2015. The 22q11.2DS participants had elevated levels of CRP (P = .004), IL-6 (P = .001), TNFα (P < .001), and IL-10 (P = .028) compared with controls. Furthermore, the psychotic 22q11.2DS participants had higher levels of IL-6 (P < .001) and IL-6/IL-10 ratio (used as an indicator for proinflammatory activation, P < .001) compared with the nonpsychotic 22q11.2DS individuals and controls. IL-6 levels and the IL-6/IL-10 ratio correlated with the severity of the cognitive deficits in the 22q11.2DS participants. Our preliminary findings indicate an involvement of inflammatory processes in the pathophysiology of psychosis and cognitive deficits in 22q11.2DS and are in line with the accumulating evidence for the role of neuroinflammation in nonsyndromic schizophrenia.
- 27 December 2017
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 78 (9) , e1219-e1225
Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits
22q11.2 deletion syndrome (22q11.2DS) is a neurogenetic disorder whose phenotype includes high rates of a schizophrenia-like psychotic disorder and immune system abnormalities. Thus, 22q11.2DS is an ideal model for studying the relationship between psychosis and inflammation. The aim of the present study was to identify inflammatory markers that may play a role in the pathophysiologic pathways associated with psychosis and cognitive deficits in 22q11.2DS. Forty-nine individuals with 22q11.2DS (13 with psychotic disorders according to DSM-IV criteria and 36 without psychotic disorders) and 30 age- and sex-matched healthy controls underwent psychiatric and cognitive assessments at an outpatient clinic. Blood samples from all participants were analyzed for C-reactive protein (CRP), interleukin (IL)-6, IL-10, tumor necrosis factor alpha (TNFα), and IL-1 receptor antagonist levels. The study was conducted between August 2014 and September 2015. The 22q11.2DS participants had elevated levels of CRP (P = .004), IL-6 (P = .001), TNFα (P < .001), and IL-10 (P = .028) compared with controls. Furthermore, the psychotic 22q11.2DS participants had higher levels of IL-6 (P < .001) and IL-6/IL-10 ratio (used as an indicator for proinflammatory activation, P < .001) compared with the nonpsychotic 22q11.2DS individuals and controls. IL-6 levels and the IL-6/IL-10 ratio correlated with the severity of the cognitive deficits in the 22q11.2DS participants. Our preliminary findings indicate an involvement of inflammatory processes in the pathophysiology of psychosis and cognitive deficits in 22q11.2DS and are in line with the accumulating evidence for the role of neuroinflammation in nonsyndromic schizophrenia.